xNOS

xNOS is a biotechnology company that specializes in developing a multi-target therapeutic compound for the treatment of endothelial dysfunction in type 2 diabetes mellitus patients. The company was founded in 2026 and has since developed a novel targeted drug candidate XOIN® (xNOSniox).

xNOS's comprehensive molecular expertise is expected to lead to a pipeline of future innovative commercial products.

Nitric oxide technology is a key focus of xNOS's strategy. xNOS's technology platform consists of validated and proprietary next-generation endothelial nitric oxide synthase (eNOS) activator therapies.